There’s a lot to be optimistic about in the Technology sector as 2 analysts just weighed in on Splunk (SPLK) and Health Catalyst (HCAT) with bullish sentiments.
Morgan Stanley analyst Keith Weiss maintained a Buy rating on Splunk today and set a price target of $246.00. The company’s shares closed last Friday at $206.75, close to its 52-week high of $208.90.
According to TipRanks.com, Weiss is a 5-star analyst with an average return of 18.9% and a 72.1% success rate. Weiss covers the Technology sector, focusing on stocks such as Palo Alto Networks, Slack Technologies, and NortonLifeLock.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Splunk with a $197.07 average price target, representing a -5.7% downside. In a report issued on June 25, Berenberg Bank also initiated coverage with a Buy rating on the stock with a $222.00 price target.
See today’s analyst top recommended stocks >>
Health Catalyst (HCAT)
In a report released today, Stephanie Davis from Leerink Partners maintained a Buy rating on Health Catalyst, with a price target of $40.00. The company’s shares closed last Friday at $32.90.
According to TipRanks.com, Davis is a 5-star analyst with an average return of 19.7% and a 62.9% success rate. Davis covers the Technology sector, focusing on stocks such as Computer Programs and Systems, Tabula Rasa HealthCare, and Nuance Communications.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Health Catalyst with a $37.70 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.